ATP stimulates PGE2/cyclin D1-dependent VSMCs proliferation via STAT3 activation: Role of PKCs-dependent NADPH oxidase/ROS generation

I-Ta Lee, Chih Chung Lin, Chao Hung Wang, Wen Jin Cherng, Jong Shyan Wang, Chuen Mao Yang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Vascular smooth muscle cells (VSMCs) that function as synthetic units play important roles in cardiovascular diseases. Extracellular nucleotides, such as ATP, have been shown to act via activation of P2 purinoceptors implicated in various inflammatory diseases, we hypothesized that extracellular nucleotides contribute to vascular diseases via up-regulation of inflammatory proteins, including cyclooxygenase-2 (COX-2) and cytosolic phospholipase A 2 (cPLA2) in VSMCs. However, the mechanisms of ATP-induced cPLA2 and COX-2 expression and PGE2 synthesis remain largely unclear. We showed that pretreatment with the inhibitors of STAT3 (CBE), NADPH oxidase [diphenyleneiodonium chloride (DPI) or apocynin (APO)], ROS [N-acetyl-l-cysteine (NAC)], and PKC (Ro-318220, Gö6983, or Rottlerin) or transfection with siRNAs of STAT3 and p47phox markedly inhibited ATPγS-induced cPLA2 and COX-2 mRNA/protein expression and promoter activity and PGE2 secretion. ATPγS further stimulated PKC, p47phox, and STAT3 translocation. Moreover, ATPγS-induced STAT3 phosphorylation and translocation was inhibited by pretreatment with the inhibitors of PKC, NADPH oxidase, and ROS. ATPγS enhanced NADPH oxidase activity and ROS generation in VSMCs, which were reduced by pretreatment with Ro-318220, Gö6983, or Rottlerin. Finally, we found that ATPγS significantly induced cyclin D1 expression and VSMCs proliferation, which were inhibited by pretreatment with NAC, APO, DPI, Ro-318220, Gö6983, Rottlerin, or CBE or transfection with siRNAs of COX-2 and cyclin D1. We also demonstrated that ATPγS induced cyclin D1 expression via a PGE2-dependent pathway. These results suggested that ATPγS-induced cPLA2/COX-2 expression and PGE2 secretion is mediated through a PKC/NADPH oxidase/ROS/STAT3-dependent pathway in VSMCs.

Original languageEnglish
Pages (from-to)954-964
Number of pages11
JournalBiochemical Pharmacology
Volume85
Issue number7
DOIs
Publication statusPublished - Apr 1 2013
Externally publishedYes

Fingerprint

NADPH Oxidase
Cyclin D1
Cell proliferation
Cyclooxygenase 2
Vascular Smooth Muscle
Dinoprostone
Phospholipases A
Smooth Muscle Myocytes
Muscle
Adenosine Triphosphate
Chemical activation
Cell Proliferation
Acetylcysteine
Chemical beam epitaxy
Transfection
Cysteine
Nucleotides
Purinergic P2 Receptors
Phosphorylation
Vascular Diseases

Keywords

  • Cyclin D1
  • Cyclooxygenase-2
  • Cytosolic phospholipase A
  • NADPH oxidase

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

ATP stimulates PGE2/cyclin D1-dependent VSMCs proliferation via STAT3 activation : Role of PKCs-dependent NADPH oxidase/ROS generation. / Lee, I-Ta; Lin, Chih Chung; Wang, Chao Hung; Cherng, Wen Jin; Wang, Jong Shyan; Yang, Chuen Mao.

In: Biochemical Pharmacology, Vol. 85, No. 7, 01.04.2013, p. 954-964.

Research output: Contribution to journalArticle

Lee, I-Ta ; Lin, Chih Chung ; Wang, Chao Hung ; Cherng, Wen Jin ; Wang, Jong Shyan ; Yang, Chuen Mao. / ATP stimulates PGE2/cyclin D1-dependent VSMCs proliferation via STAT3 activation : Role of PKCs-dependent NADPH oxidase/ROS generation. In: Biochemical Pharmacology. 2013 ; Vol. 85, No. 7. pp. 954-964.
@article{943e2b78dd4743be8e8a982d8ce64f09,
title = "ATP stimulates PGE2/cyclin D1-dependent VSMCs proliferation via STAT3 activation: Role of PKCs-dependent NADPH oxidase/ROS generation",
abstract = "Vascular smooth muscle cells (VSMCs) that function as synthetic units play important roles in cardiovascular diseases. Extracellular nucleotides, such as ATP, have been shown to act via activation of P2 purinoceptors implicated in various inflammatory diseases, we hypothesized that extracellular nucleotides contribute to vascular diseases via up-regulation of inflammatory proteins, including cyclooxygenase-2 (COX-2) and cytosolic phospholipase A 2 (cPLA2) in VSMCs. However, the mechanisms of ATP-induced cPLA2 and COX-2 expression and PGE2 synthesis remain largely unclear. We showed that pretreatment with the inhibitors of STAT3 (CBE), NADPH oxidase [diphenyleneiodonium chloride (DPI) or apocynin (APO)], ROS [N-acetyl-l-cysteine (NAC)], and PKC (Ro-318220, G{\"o}6983, or Rottlerin) or transfection with siRNAs of STAT3 and p47phox markedly inhibited ATPγS-induced cPLA2 and COX-2 mRNA/protein expression and promoter activity and PGE2 secretion. ATPγS further stimulated PKC, p47phox, and STAT3 translocation. Moreover, ATPγS-induced STAT3 phosphorylation and translocation was inhibited by pretreatment with the inhibitors of PKC, NADPH oxidase, and ROS. ATPγS enhanced NADPH oxidase activity and ROS generation in VSMCs, which were reduced by pretreatment with Ro-318220, G{\"o}6983, or Rottlerin. Finally, we found that ATPγS significantly induced cyclin D1 expression and VSMCs proliferation, which were inhibited by pretreatment with NAC, APO, DPI, Ro-318220, G{\"o}6983, Rottlerin, or CBE or transfection with siRNAs of COX-2 and cyclin D1. We also demonstrated that ATPγS induced cyclin D1 expression via a PGE2-dependent pathway. These results suggested that ATPγS-induced cPLA2/COX-2 expression and PGE2 secretion is mediated through a PKC/NADPH oxidase/ROS/STAT3-dependent pathway in VSMCs.",
keywords = "Cyclin D1, Cyclooxygenase-2, Cytosolic phospholipase A, NADPH oxidase",
author = "I-Ta Lee and Lin, {Chih Chung} and Wang, {Chao Hung} and Cherng, {Wen Jin} and Wang, {Jong Shyan} and Yang, {Chuen Mao}",
year = "2013",
month = "4",
day = "1",
doi = "10.1016/j.bcp.2012.12.016",
language = "English",
volume = "85",
pages = "954--964",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - ATP stimulates PGE2/cyclin D1-dependent VSMCs proliferation via STAT3 activation

T2 - Role of PKCs-dependent NADPH oxidase/ROS generation

AU - Lee, I-Ta

AU - Lin, Chih Chung

AU - Wang, Chao Hung

AU - Cherng, Wen Jin

AU - Wang, Jong Shyan

AU - Yang, Chuen Mao

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Vascular smooth muscle cells (VSMCs) that function as synthetic units play important roles in cardiovascular diseases. Extracellular nucleotides, such as ATP, have been shown to act via activation of P2 purinoceptors implicated in various inflammatory diseases, we hypothesized that extracellular nucleotides contribute to vascular diseases via up-regulation of inflammatory proteins, including cyclooxygenase-2 (COX-2) and cytosolic phospholipase A 2 (cPLA2) in VSMCs. However, the mechanisms of ATP-induced cPLA2 and COX-2 expression and PGE2 synthesis remain largely unclear. We showed that pretreatment with the inhibitors of STAT3 (CBE), NADPH oxidase [diphenyleneiodonium chloride (DPI) or apocynin (APO)], ROS [N-acetyl-l-cysteine (NAC)], and PKC (Ro-318220, Gö6983, or Rottlerin) or transfection with siRNAs of STAT3 and p47phox markedly inhibited ATPγS-induced cPLA2 and COX-2 mRNA/protein expression and promoter activity and PGE2 secretion. ATPγS further stimulated PKC, p47phox, and STAT3 translocation. Moreover, ATPγS-induced STAT3 phosphorylation and translocation was inhibited by pretreatment with the inhibitors of PKC, NADPH oxidase, and ROS. ATPγS enhanced NADPH oxidase activity and ROS generation in VSMCs, which were reduced by pretreatment with Ro-318220, Gö6983, or Rottlerin. Finally, we found that ATPγS significantly induced cyclin D1 expression and VSMCs proliferation, which were inhibited by pretreatment with NAC, APO, DPI, Ro-318220, Gö6983, Rottlerin, or CBE or transfection with siRNAs of COX-2 and cyclin D1. We also demonstrated that ATPγS induced cyclin D1 expression via a PGE2-dependent pathway. These results suggested that ATPγS-induced cPLA2/COX-2 expression and PGE2 secretion is mediated through a PKC/NADPH oxidase/ROS/STAT3-dependent pathway in VSMCs.

AB - Vascular smooth muscle cells (VSMCs) that function as synthetic units play important roles in cardiovascular diseases. Extracellular nucleotides, such as ATP, have been shown to act via activation of P2 purinoceptors implicated in various inflammatory diseases, we hypothesized that extracellular nucleotides contribute to vascular diseases via up-regulation of inflammatory proteins, including cyclooxygenase-2 (COX-2) and cytosolic phospholipase A 2 (cPLA2) in VSMCs. However, the mechanisms of ATP-induced cPLA2 and COX-2 expression and PGE2 synthesis remain largely unclear. We showed that pretreatment with the inhibitors of STAT3 (CBE), NADPH oxidase [diphenyleneiodonium chloride (DPI) or apocynin (APO)], ROS [N-acetyl-l-cysteine (NAC)], and PKC (Ro-318220, Gö6983, or Rottlerin) or transfection with siRNAs of STAT3 and p47phox markedly inhibited ATPγS-induced cPLA2 and COX-2 mRNA/protein expression and promoter activity and PGE2 secretion. ATPγS further stimulated PKC, p47phox, and STAT3 translocation. Moreover, ATPγS-induced STAT3 phosphorylation and translocation was inhibited by pretreatment with the inhibitors of PKC, NADPH oxidase, and ROS. ATPγS enhanced NADPH oxidase activity and ROS generation in VSMCs, which were reduced by pretreatment with Ro-318220, Gö6983, or Rottlerin. Finally, we found that ATPγS significantly induced cyclin D1 expression and VSMCs proliferation, which were inhibited by pretreatment with NAC, APO, DPI, Ro-318220, Gö6983, Rottlerin, or CBE or transfection with siRNAs of COX-2 and cyclin D1. We also demonstrated that ATPγS induced cyclin D1 expression via a PGE2-dependent pathway. These results suggested that ATPγS-induced cPLA2/COX-2 expression and PGE2 secretion is mediated through a PKC/NADPH oxidase/ROS/STAT3-dependent pathway in VSMCs.

KW - Cyclin D1

KW - Cyclooxygenase-2

KW - Cytosolic phospholipase A

KW - NADPH oxidase

UR - http://www.scopus.com/inward/record.url?scp=84874658797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874658797&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2012.12.016

DO - 10.1016/j.bcp.2012.12.016

M3 - Article

C2 - 23318226

AN - SCOPUS:84874658797

VL - 85

SP - 954

EP - 964

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 7

ER -